Navigation Links
NanoBio Corporation Announces Positive Phase 1 Clinical Results for,Topical Treatment for Onychomycosis

ANN ARBOR, Mich., May 22, 2007 /PRNewswire/ -- NanoBio Corporation, a biopharmaceutical company developing novel products for the treatment and prevention of serious infections, today announced positive safety data from its Phase 1 clinical study of NB-002, the company's drug candidate currently in a Phase 2 clinical trial for the topical treatment of onychomycosis.

The Phase 1 clinical study was completed in January 2007 and involved 20 subjects who received twice-daily treatments of NB-002 (0.25% or 0.5%) for 28 days. Subjects were examined on days 1, 3, 7, 14, 28 and 58 for adverse events, dermal irritation and pharmacokinetic sampling. There were no drug- related adverse events, serious adverse events or discontinuations due to adverse events in any of the subjects treated. In addition, plasma drug levels were below the limit of detection (1 ng/mL) at all time points. Based on the remarkable safety profile demonstrated in this clinical study as well as other previously conducted clinical and toxicology studies, a 42-week double-blinded Phase 2 clinical study of NB-002 was initiated by NanoBio in the first quarter of 2007.

James R. Baker, MD, NanoBio's Chairman of the Board and Chief Science Officer, commented, "A unique aspect of products derived from the company's NanoStat(TM) technology is that the treatments are not systemically absorbed and they are selectively toxic to microbes while non-irritating to the skin and mucous membranes. This Phase 1 safety data further confirms that NB-002 will offer a safe alternative to the currently available systemic products. This is a critical factor for individuals affected by onychomycosis, given approximately 95% of people with this disease remain untreated as a result of the serious toxicities associated with the oral medications on the market."

Phase 2 Clinical Study for NB-002

A randomized, double-blinded, placebo-controlled Phase 2 c
'"/>




Page: 1 2 3

Related medicine technology :

1. Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. Millipore Corporation Announces New ReNcell Data from Collaboration with ReNeuron
3. Alba Therapeutics Corporation Reports Preliminary Phase IIa Clinical Trial Results for AT-1001 for the Treatment of Celiac Disease
4. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:12/24/2014)... , Dec. 24, 2014  The International Trade Commission (ITC) ... (RMD) against BMC Medical. In a notice issued on December ... that ResMed,s patent on its humidifier was invalid. ... "monumental win". "We are very excited with the ITC,s decision ... that we have taken since the very beginning on the ...
(Date:12/24/2014)... 2014  Diplomat Pharmacy, Inc. (NYSE: DPLO ... to announce Jennifer Hagerman , Pharm.D., AE-C, senior ... office as the president of the Michigan Pharmacists Association ... take place Feb. 28, 2015, at the MPA Annual ... Renaissance Center in Detroit, Michigan . ...
(Date:12/24/2014)... NEW YORK and LONDON ... in global orthopedic industry are expected to grow at ... consumption in terms of value and volume. Hip, knee ... the developed world while in emerging economies they have ... failure rates are challenging the use of composites. Non-metallic ...
Breaking Medicine Technology:ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 2Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 3Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3
... 15 Inverness Medical Innovations, Inc. (NYSE: IMA ... their health at home through the merger of rapid diagnostics and ... Alere Inc., after shareholders approved the name change at its Annual ... Company also announced that it expects its NYSE stock symbol to ...
... LAKE FOREST, Ill. , July 15 ... on the healthcare industry, announced today the closing of its third ... second captive subordinated debt fund of $200 million ("Capital ... million in March 2002 and its second equity ...
Cached Medicine Technology:RoundTable Healthcare Partners Closes Two Funds 2RoundTable Healthcare Partners Closes Two Funds 3
(Date:12/26/2014)... 2014 Plugin and template developers from ... Plugin for Final Cut Pro X. , “TransPack Volume 5 ... to pull off an industry professional look” Said Christina Austin, ... on TransPack Volume 5, a new level of professionalism will ... of over 50 Final Cut Pro X transitions featuring organic ...
(Date:12/26/2014)... Pentec Health, Inc. number fourteen on the Best ... 2014. The awards program, created in 2000, is one ... the country. The program is a public/private partnership between ... Economic Development, the Pennsylvania State Council of the Society ... Journal. , Charlie Wilson, Vice President of ...
(Date:12/25/2014)... 26, 2014 The microscopy market ... 7.2% to reach $5,756.0 million by 2019. Optical ... market. The electron microscopes product segment is expected ... period. , Rising focus on nanotechnology, technological advancements, ... the microscopy market. , Get Full Copy of ...
(Date:12/25/2014)... 2014 The report “Nintedanib (Colorectal ... focuses on the current treatment landscape, unmet needs, ... cancer market. Stivarga is a drug which is ... cancer. Boehringer Ingelheim is developing nintedanib (BIBF-1120), an ... refractory CRC in the US, Europe, and Japan. ...
(Date:12/25/2014)... 2014 “Every three months the trends for ... sweetheart evening dress will be one of the hottest styles ... Yunx.co.uk says. Today, the company releases 26 A-line sweetheart evening ... 80% off. , “We are trying our best to ... our latest designs. Along with affordable prices, we provide discounted ...
Breaking Medicine News(10 mins):Health News:Today a new plugin was announced from Pixel Film Studios, TransPack Volume 5 for Final Cut Pro X 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4
... been a considerable increase in the number of repeat cesarean ... 8-year study conducted between 1996 and 2003 survey has further ... unexplained reasons. ,According to National statistics, there has ... in women who have had a cesarean. Concomitantly, there has ...
... first step to retaining a good memory as we age is ... that they could control their memory are more likely to use ... ,The researchers analyzed the link between a sense of control ... and 83 years. The study participants were required to recall a ...
... pollution could be responsible for increase in cardiac and ... the recent issue of JAMA. , The ... disorders have been highlighted by numerous environment based studies. ... health is being perceived as a major public health ...
... of an association between aluminum salts contained in deodorants ... like cadmium and aluminum are believed to exert estrogen-like ... ,Under laboratory conditions, these salts have even ... cell lines, highlighting the carcinogenic potential of such compounds, ...
... increased over the last 10 years, a survey has found. ... ,A South Australian survey conducted between 1990 and 2003 ... from 7.3 percent in 1990 to 14.6 percent in 2003. ... people aged 55 and above. Overall the prevalence rate rose ...
... University of Illinois at Urbana-Champaign developed an innovative ... new drug and agricultural materials and delivery vehicles. ... engineering, chemistry and physics said that it was ... biofunctional capsules could be used in drug delivery, ...
Cached Medicine News:Health News:Want To Retain Your Memory? Believe That You Can Do So! 2Health News:Air Pollution Exposure Increases Risk Of Heart And Respiratory Disease 2Health News:Aluminum Salts In Underarm Deodorants Increase Risk Of Breast Cancer 2Health News:Medical Boon in the Form of a Biofriendly Capsule 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: